MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-12-31.

Income Overview

Net Income
-$1,999,397
EPS
-$0.05
Unit: Dollar

Income Statement
2025-12-31
2025-09-30
2025-06-30
Research and development
1,164,737 809,991 1,074,985.25*
General and administrative
1,455,173 1,450,269 1,230,885*
Total operating expenses
2,619,910 2,260,260 2,305,870.25
Loss from operations
-2,619,910 -2,260,260 -2,305,870.25*
Interest expense
17,439 17,439 95,503.5*
Interest income
85,410 109,616 64,478.25*
Grant income
552,576 9,825 216,003.5*
Other
-34 -96 -298.75*
Other income, net
620,513 101,906 184,679.5*
Net loss
-1,999,397 -2,158,354 -2,121,190.75
Basic EPS
-0.05 -0.05 -0.063
Diluted EPS
-0.05 -0.05 -0.063
Basic Average Shares
41,084,731 41,084,731 33,820,306
Diluted Average Shares
41,084,731 41,084,731 33,820,306
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Grant income$552,576 Interest income$85,410 Net loss-$1,999,397 Other income, net$620,513 Interest expense$17,439 Other-$34 Loss from operations-$2,619,910 Total operatingexpenses$2,619,910 General andadministrative$1,455,173 Research and development$1,164,737

Anebulo Pharmaceuticals, Inc. (ANEB)

Anebulo Pharmaceuticals, Inc. (ANEB)